UK markets closed

Freeline Therapeutics Holdings plc (FRLN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.7325-0.0118 (-1.59%)
As of 01:09PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 48.55M
Enterprise value -4.79M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.41
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.04

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-91.47%
S&P500 52-week change 3-6.14%
52-week high 315.4000
52-week low 30.6500
50-day moving average 30.9589
200-day moving average 32.1583

Share statistics

Avg vol (3-month) 3212.13k
Avg vol (10-day) 363.9k
Shares outstanding 564.73M
Implied shares outstanding 6N/A
Float 8275.08M
% held by insiders 10.00%
% held by institutions 163.57%
Shares short (28 Apr 2022) 4295.67k
Short ratio (28 Apr 2022) 41.08
Short % of float (28 Apr 2022) 4N/A
Short % of shares outstanding (28 Apr 2022) 40.48%
Shares short (prior month 30 Mar 2022) 4344.44k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-38.35%
Return on equity (ttm)-78.21%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -129.99M
Net income avi to common (ttm)-132.18M
Diluted EPS (ttm)-3.5330
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)113.1M
Total cash per share (mrq)0.18
Total debt (mrq)59.63M
Total debt/equity (mrq)50.29
Current ratio (mrq)4.82
Book value per share (mrq)0.19

Cash flow statement

Operating cash flow (ttm)-99.92M
Levered free cash flow (ttm)-51.53M